
Gordon Chan
549 posts


@investseekers @dma0040 Based on the performance of $NVO today, if the pricing close to US$50 before earning report, I will reduce the position of $NVO again.......
English

Consensus expects $NVO to report Q2 revenue of DKK 71.3B and adjusted EBIT of DKK 28.7B when it reports earnings on Wednesday.
Analysts expect continued weakness in the diabetes franchise, with Ozempic sales of DKK 26.7B, down from DKK 30.5B a year ago, and Rybelsus sales of DKK 4.7B versus DKK 5.6B.
Obesity is expected to remain the bright spot. Analysts forecast Wegovy sales of DKK 19.1B, while Oral Wegovy is expected to contribute another DKK 3.3B in just its second reported quarter.
English

@investseekers BAD NEWS again.....For the coming earning report, we may facing the other bad news.....
English

$NVO reported that its Phase 3 ZEUS study of ziltivekimab failed to reduce the risk of heart attacks, strokes, or cardiovascular death.
Although the drug successfully lowered inflammation, it did not improve cardiovascular outcomes compared with placebo in patients with cardiovascular disease and chronic kidney disease.
Novo Nordisk said the result will not change its 2026 operating profit outlook but will result in a non cash impairment charge in Q3. The company also confirmed that two other late stage studies of ziltivekimab in heart failure and heart attack patients will continue, with results expected in the first half of 2027.
Link: novonordisk.com/content/nncorp…
#stocks #Investing
English

@novonordisk OMG.....any BAD news for $NVO , it must drop 10% of stock price......
For the coming earning report, the second BAD news may be released.....
English

#PRESS We are announcing top-line results from a phase 3 cardiovascular outcomes trial.
Learn more in the company announcement here: novonordisk.com/content/nncorp…

English

@JowiPozoX The logo is $INTC , and the content is $INTU ....
English

@JeppesenRj @ResearchPulse1 Need time to prove it....The stock price still under pressure.
English

We are now at over 300,000 weekly, and when we include the UAE, the UK, and the EU from 2027, that figure will be at least 500,000 per week, possibly double.
500,000 × 4 weeks = 2 million
× 12 months = 24 million
× an average of DKK 1,000
That amounts to DKK 24 billion per year from tablets alone.
But it will probably be twice that.
English

Wegovy pill sales in US breaks $50 million mark per week.
That’s a run rate above $2.6B. Plus UAE and UK sales
Many Analysts still behind the curve
$LLY $NVO $VKTX
ResearchPulse@ResearchPulse1
English

@Aktieland We are looking for the Q2 earning report and prove that $NVO still growing up in the market. HOPE we can meet the first price target around USD $53-$55/share.
English

📈 The oral GLP-1 battle has a clear leader—for now.
Weekly prescriptions:
🔵 Wegovy pill: ~165K
🔴 Foundayo: ~22K
The race is far from over, but today the scoreboard clearly favors $NVO.
#GLP1 #NovoNordisk #Investing $LLY $HIMS

English

@Redpulse_News The most important that is Buying Vol. It needs more buying power to increase the stock price. If the Q2 earning report meet the expectation and upgrade the 2026 revenue, then $NVO will up to $53 to $55.
English

@Redpulse_News Any BAD NEWS for $NVO ? It drops -1.8% at the pre-market.
English

@investseekers But I found the BIG DROP (-1.85%) for $NVO. Roche affect the earning report (Q22026) for $NVO ? $NVO
English

$NVO
Roche reported better than expected Q2 sales for its hemophilia drug Hemlibra.
Hemlibra generated CHF 1.30 billion in sales, up 9% year over year and ahead of Bloomberg consensus of CHF 1.23 billion.
Hemlibra competes with Novo's NovoSeven in hemophilia, making the stronger than expected performance relevant for Novo Nordisk investors.
#stocks #Investing
English

@investseekers When are Novo's Q2 earnings expected to be released?
English

@StockChaser_ Haha, I just need $NVO up 86%, and I will sell out all of them🤣🤣🤣🤣🤣
English

@Aktieland Actually, I hope we can get the BIG returns from $NVO. 🥳🥳🥳
English

@GordonChan4008 That's exactly why I think $NVO may be the most attractive opportunity among them.
Price to perfection vs. price to pessimism.
English

@investseekers Then, how can we get the sell through in UK market? Thanks Bro
English

Early demand for $NVO 's oral Wegovy appears to be strong in the UK.
According to a survey by the National Pharmacy Association, 71% of UK pharmacies have already received enquiries from patients looking to start treatment just days after launch.
"The demand has definitely been noticeable," said National Pharmacy Association Chair Olivier Picard.
Another pharmacist described a "significant increase" in enquiries, adding: "There has been a real buzz and a lot of excitement."
Oral Wegovy became available through UK private pharmacies this week following its recent approval.
Link to article: ft.com/content/5bb61b…
#stocks #Investing
English

全球最大的金融网络Swift在今天宣布开发的区块链已经正式上线,首批接入了17家银行开展24/7代币化存款的跨境支付,从而实现秒到账,不再需要等待各个不同国家银行的营业时间,并且号称每3天就可以在200多个国家转移全球GDP的资金,这是传统金融体系对区块链和代币化迈出最大的一步,但也只能说迈出了半步,毕竟依然用的是联盟链,不过这也情有可原,但是转移的资金也依然不是USDT、USDC等任何一个稳定币,而是银行自己的代币化存款,只在Swift银行体系内部流转,所以这是以Swift牵头全球银行联合发起的一场防御反击战。
毕竟稳定币实时转账的优势摆在这里,如果Swift和银行再不行动,则很多企业会选择把银行存款换成稳定币,银行会失去存款,而Swift也会失去结算地位,所以Swift就拉着这些银行把自己的存款代币化,至少保证在原有体系里的资金不会流出去。

中文

Trading volume in Novo Nordisk remains surprisingly low.
After roughly two hours of trading, only 1.8 million shares have changed hands versus an average daily volume of 14.8 million.
That doesn't suggest broad-based panic selling.
$NVO #NovoNordisk

English

@AlphaBeta_2017 @bullrunalpha It is because $Coin and $CRCL will review the working contract on Aug,2026. May be $Coin want to increase the bargaining power when dealings with $CRCL.
English

@bullrunalpha Why does $COIN join the consortium? I don’t get it.
English





















